Back to search

University of Crete (UOC)

Αλληλεπίδραση ανάμεσα στην Α-Συνουκλεϊνη και το λυσόσωμα σε νευροεκφυλιστικές παθήσεις

Abstract

dc:description

My doctoral work has focused primarily on the chaperone-mediated autophagy (CMA) protein degradation pathway and its involvement in neurodegenerative disease: in particular its interaction with the small peptide α-synuclein (SNCA), which is implicated in the pathology of Parkinson Disease (PD) - a progressive neurodegenerative disorder affecting midbrain dopamine neurons of the substantia nigra pars compacta (SNpc).CMA is a substrate-specific lysosomal proteolytic pathway that entails direct translocation of substrates to the lysosomal lumen following recognition by a cytosolic chaperone-complex. In spite of the multiple molecular players involved, the primary rate-limiting step for the CMA pathway is now known to be levels of the LAMP2A receptor at the lysosomal membrane. Thus, it stands to reason that regulating LAMP2a levels is the bona fide throttle for this proteolytic pathway. SNCA, a 14 kDa peptide preferentially localized in presynaptic nerve terminals – with functions yet unknown – is an important site for genetic alterations in both familial and sporadic forms of PD. In particular, both missense and multiplication mutations have been identified in familial PD, whereas polymorphsims within the SNCA gene encoding for the α-synuclein protein have been identified in sporadic PD through large genome-wide associated studies (GWAS). Furthermore, it is also the primary constituent of Lewy Bodies (LBs) and Lewy Neurites (LNs), proteinacious inclusions found inside the affected neuronal cell bodies and neurites of PD diseased brains – and the hallmark diagnostic sign of PD pathology. Other diseases, most notably Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB), also demonstrate characteristic SNCA accumulation and aggregation, and are collectively termed “synucleinopathies” - as it is thought this process of SNCA aggregation is central not only to their post-mortem diagnosis, but also to their pathogenesis. This knowledge, and in particular the cases with SNCA multiplications, have led to the notion of the great importance of α-synuclein burden within neuronal and glial cells in the etiopathogenesis of the synucleinopathies. Hence, the great importance of identifying mechanisms through which SNCA may be degraded within such cells. Studies by our group and others have shown that SNCA is primarily degraded in neuronal cells by CMA, and as PD-associated SNCA mutants specifically inhibit this proteolytic pathway, their interrelationship has been subject of much debate and study in the context of neurodegenerative disease; and, it has been the primary focus of this dissertation work. Initially, our aim was to investigate the in vivo therapeutic potential of enhancing CMA as a means to combat PD-like neurodegeneration. To this end, we overexpressed LAMP2A in the vulnerable dopaminergic neurons of the SNpc using direct stereotactic delivery of recombinant adeno-associated viruses (rAAVs) in an attempt to protect against rAAV-overexpressed WT SNCA-induced neurotoxicity. We found LAMP2A overexpression to completely rescue SNpc neurons from SNCA-associated neurodegeneration whilst preventing aggregation of the protein. Thus, we concluded LAMP2A overexpression to be a viable therapeutic strategy in protecting against SNCA-induced neurotoxicity in a well-established established animal model of PD. The paper, published in the June 2013 edition of Brain, was among the first ever to demonstrate successful protection against SNCA-induced neurodegeneration in vivo. Based on these findings, we moved to test the reciprocal question arising from the beneficial effects of boosted CMA function: could CMA dysfunction be equally detrimental in vivo in the rat brain? Though CMA function has been implicated in disease pathogenesis, with several studies detailing its interactions with disease-associated peptides – SNCA being a prime example – little is known about its physiological significance in the healthy CNS and the in vivo impact of its dysfunction. CMA markers are indeed reduced in the ageing and Parkinsonian brain, but are they the cause or the effect?To answer these outstanding questions, we utilized our now well-established method of in vivo transduction of dopaminergic neurons by rAAVs and generated two LAMP2a-targeted shRNA vectors designed to knock down endogenous LAMP2a levels in the rat SNpc, as well as a scrambled control sequence, and stereotactically delivered them to the rat SNpc.We found LAMP2A protein levels in transduced neurons to be ≈50% reduced, in turn causing severe degeneration of SNpc neurons at 8 weeks post-injection, preceded by axonal degeneration and dopamine loss in the striatum after 4 weeks. Furthermore, we found accumulation of endogenous, soluble SNCA in the soma of affected neurons, with significant compensatory induction of other proteolytic pathways and robust neuroinflammation in the surrounding area. This loss of dopaminergic innervation also resulted in significant behavioral impairments at 8- and 12 weeks post-injection. Taken together, this study demonstrated – for the first time – the ramifications of CMA impairments in the established nigrostriatal circuit, and at present time the findings have been accepted for publication in the journal Autophagy. Though these projects underline the importance of proper CMA function in the maintenance of neuronal homeostasis, especially in regards to the clearance of both overexpressed- and endogenous SNCA, less is known about other potential pathways potentially impacted by altered CMA. We hypothesized there could be yet unknown substrates with essential neuronal functions that were dependent on proper CMA-mediated turnover. In an attempt to elucidate which, if indeed any, portion of the neuronal proteome was significantly impacted by manipulating CMA function, we used a system of primary rat cortical neuronal cultures in conjunction with our viral vectors to either overexpress LAMP2A (AV-vector), or downregulate it by the same shRNA target vectors utilized in the previous project (now embedded in a LV-vector).To carry out such an exhaustive proteomics study we collaborated with the lab of Dr. Antonia Vlahou, and carried out MS/MS-coupled 2D-PAGE analysis of whole-cell lysates from transduced neuronal cultures, ultimately identifying 56 peptides whose abundance was significantly altered by altered CMA function. Two of these peptides, DJ-1 – an antioxidant involved in familial PD, and CRMP-2 – a pro-neuronal factor involved in schizophrenia – were selected for further analysis, and we identified distinct phenotypic alterations stemming from LAMP2A downregulation that could be rescued by restoring levels of each of these peptides. Importantly, overexpressing either of them in the absence of CMA inhibition elicited no detectable phenotypic alterations, and we felt safe to conclude the effects were dependent on the state of CMA function in the cell. As the whole list of peptides encompassed several functional categories, yet more downstream consequences of impaired CMA could be awaiting discovery. At the time of writing this thesis, these findings are being prepared for submission.We naturally carried out several experiments that did not fit with the major themes of the above publications, and as such have not been published or incorporated in any manuscript at this point in time. For instance, we made several attempts in primary neurons to elucidate the proteolytic profile of LRRK2 - a kinase implicated in PD pathogenesis - and we found it too to be significantly reduced upon LAMP2A downregulation: as was the case with DJ-1 and CRMP-2. We furthermore replicated these findings using general lysosomal inhibition, whilst specific inhibitors of the primary mode of lysosomal degradation - macroautophagy (MA) – produced no effects. As such, we speculated CMA-impairments to specifically produce these effects on LRRK2 – possibly through induction of the non-lysosomal ubiquitin-proteasome system (UPS). Whilst we did find pre-treatment with a general lysosomal inhibitor to attenuate the response of cells to UPS inhibition, such inhibitors were too toxic in our hands to be used in cohort with viral-mediated LAMP2A downregulation, and we could not verify this effect to be truly CMA-specific. At present time, we are looking into less cytotoxic methods for UPS-inhibition to be able to ascertain any functional connection between it and CMA. Taken together, the work underlying this dissertation work has demonstrated some important things. First and foremost, LAMP2A overexpression is a viable therapeutic strategy in treating synucleinopathies, as the induction of CMA prevents SNCA aggregation and neurotoxicity. Secondly, CMA failure by LAMP2A depletion or inhibition could very well be first the step towards cell death in many of these ailments, with protein accumulation and aberrant activity of other proteolytic pathways in large part acting downstream of this initial insult. Last, but not least, through induction of said pathways – or through other mechanisms altogether – CMA failure could indirectly cause the deregulation of several essential peptides with detrimental net outcomes for the cell. As several studies have begun to tap into the field of non-invasive methods for CMA upregulation in humans – through either pharmacological compounds or other constructs capable of blood-brain barrier transfer, these mechanisms can be exploited to potentially mitigate neurodegeneration in the wide variety of diseases in which SNCA – or failing CMA - is a major player.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Brekk, Oeystein Roed

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38515

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Brekk, Oeystein Roed. Αλληλεπίδραση ανάμεσα στην Α-Συνουκλεϊνη και το λυσόσωμα σε νευροεκφυλιστικές παθήσεις. University of Crete (UOC), 2016. http://hdl.handle.net/10442/hedi/38515